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Effect of Immune Activation during 
Early Gestation or Late Gestation 
on Inhibitory Markers in Adult Male 
Rats
Tasnim Rahman1,2, Cynthia Shannon Weickert1,2,3, Lauren Harms4,5,6, Crystal Meehan4,5,6,7, 
Ulrich Schall5,6,8, Juanita Todd4,5,6, Deborah M. Hodgson4,5,6, Patricia T. Michie4,5,6 & 
Tertia Purves-Tyson1,2*
People with schizophrenia exhibit deficits in inhibitory neurons and cognition. The timing of maternal 
immune activation (MIA) may present distinct schizophrenia-like phenotypes in progeny. We 
investigated whether early gestation [gestational day (GD) 10] or late gestation (GD19) MIA, via viral 
mimetic polyI:C, produces deficits in inhibitory neuron indices (GAD1, PVALB, SST, SSTR2 mRNAs) 
within cortical, striatal, and hippocampal subregions of male adult rat offspring. In situ hybridisation 
revealed that polyI:C offspring had: (1) SST mRNA reductions in the cingulate cortex and nucleus 
accumbens shell, regardless of MIA timing; (2) SSTR2 mRNA reductions in the cortex and striatum of 
GD19, but not GD10, MIA; (3) no alterations in cortical or striatal GAD1 mRNA of polyI:C offspring, but 
an expected reduction of PVALB mRNA in the infralimbic cortex, and; (4) no alterations in inhibitory 
markers in hippocampus. Maternal IL-6 response negatively correlated with adult offspring SST mRNA 
in cortex and striatum, but not hippocampus. These results show lasting inhibitory-related deficits in 
cortex and striatum in adult offspring from MIA. SST downregulation in specific cortical and striatal 
subregions, with additional deficits in somatostatin-related signalling through SSTR2, may contribute 
to some of the adult behavioural changes resulting from MIA and its timing.
Neural activity between the cortex and striatum regulates motor, cognitive, and limbic function, and aspects of 
these modalities are perturbed in people with schizophrenia1,2. This neural activity is influenced by local inhib-
itory neurons, and the dysregulation of inhibition is postulated as a central contributor in the development of 
schizophrenia. Inhibitory tone is mainly established during early neurodevelopment to coordinate efficient neu-
rotransmission3,4. Inhibitory interneurons migrate from the ganglionic eminence and the subventricular zone 
through the white matter to reach their destination in the cortical grey matter (see5 for review) and hippocampus 
(see6 for review). Striatal neurons are largely generated from the ganglionic eminences7. Perturbations during this 
neurodevelopmental epoch is therefore postulated to dysregulate inhibitory tone in the brain8 and contribute to 
the behavioural phenotypes in schizophrenia (see9,10 for review).
Glutamate decarboxylase-1 (GAD1) is one of the enzymes that catalyses the main inhibitory neurotransmitter 
in the brain, gamma-aminobutyric acid (GABA)11. There are two main subsets of GABAergic neurons that are 
distinguished based on their expression of the calcium-binding protein, parvalbumin (PVALB), or the neuro-
peptide hormone, somatostatin (SST) (see12 for review). Studies in post-mortem human brain show that schizo-
phrenia cases have reduced cortical13, hippocampal14,15, and striatal16,17 GABAergic indices that suggest that these 
regions may contribute to the cognitive deficits exhibited by people with schizophrenia. The most consistently 
reported inhibitory deficits in the cortex of people with schizophrenia include reductions in GAD118,19, PVALB8,20, 
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and SST8,21–24 mRNAs. SST also elicits inhibition via somatostatin receptors (see25 for review), and decreases in 
SST receptor 2 (SSTR2) mRNA is reported in the dorsolateral prefrontal cortex (dlPFC) of people with schiz-
ophrenia26. Whether it is proliferation, differentiation, migration, survival and/or function of these inhibitory 
neurons that contribute to schizophrenia pathophysiology is unclear.
One way to test the gap in knowledge regarding the origin of inhibitory neuropathology involves recapitu-
lating epidemiological factors that increase the risk of schizophrenia in animal models. Epidemiological inves-
tigations show gestational and perinatal infection increases the risk of schizophrenia in progeny27–32. In rodent 
studies, maternal immune activation (MIA) can be induced in pregnant dams with the viral mimic polyribo-
inosinic:polyribocytidilic acid (polyI:C). This results in offspring (henceforth referred to as polyI:C offspring) 
that exhibit schizophrenia-like neuroanatomical changes at adulthood (such as reduced brain volume in cortical, 
striatal, and hippocampal regions33) and schizophrenia-like behavioural changes (such as deficits in sensorimo-
tor gating34,35, increased amphetamine-induced hyperlocomotion34, and impaired learning36). This suggests MIA 
may contribute to neurobiological alterations in these brain regions in offspring. Indeed, reductions in GABA 
in cortex37, and GAD1 mRNA in cortex and hippocampus38,39 are found in polyI:C offspring. SST and PVALB 
neuron populations are trophically dependent on trkB40–43, and preliminary studies show alterations in the gene 
expression of trkB in the striatum of adult male polyI:C offspring44. This suggests that inhibitory neuron deficits 
may occur in the striatum of male polyI:C offspring.
The timing of MIA exposure is associated with distinct behavioural changes that may be associated with 
distinct neurobiological changes that contribute to these behaviours in offspring at adulthood45–47. Indeed, the 
timing of MIA exposure determines the extent and pattern of brain changes in foetal neurodevelopment (see48 
for review). In mice, early gestation MIA exposure results in offspring with behaviours that mimic positive symp-
toms of schizophrenia, and late gestation MIA exposure results in offspring with more negative and cognitive 
schizophrenia-like symptoms49. In rats, we found that early gestation MIA exposure results in male offspring with 
sensorimotor gating deficits, whilst late gestation MIA exposure results in male and female offspring with both 
sensorimotor gating and working memory deficits50. This suggests that the timing of MIA exposure on related 
neurobiological changes may be more apparent in male offspring versus female offspring.
Based on key neurotransmitter systems implicated in schizophrenia, our previous studies on the timing of 
MIA probed dopaminergic50 and glutamatergic51 indices in this model. For example, we recently reported that 
polyI:C offspring, from either early gestation MIA or late gestation MIA, exhibit glutamatergic alterations that are 
more pronounced in male offspring, and thus may relate to the sensorimotor gating deficits that are exacerbated 
in male polyI:C offspring51. Although studies in mice show that MIA is sufficient to reduce PVALB-positive cells 
in the medial prefrontal cortex in both early gestation and late gestation adult49,52 and juvenile53 polyI:C offspring, 
to our knowledge, there have been no studies on the effects of MIA, or the timing of MIA, on inhibitory neuron 
markers in the cortex, striatum, and hippocampus in rats.
The initial formation of the ganglionic eminence occurs at gestational day (GD) 10 54, whereas interneurons 
(from the subventricular zone into the cortical plate) tangentially migrate from GD18 into the first postnatal 
weeks55,56. As the development of cortical inhibitory interneurons is a relatively protracted process, we hypoth-
esised that the impact of gestational inflammation on inhibitory markers in different brain regions at adulthood 
would vary depending on the timing of MIA. Therefore, in the current study we investigated the effects of early 
gestation (GD10) or late gestation (GD19) polyI:C-induced MIA on gene expression of inhibitory indices (GAD1, 
PVALB, SST, and SSTR2) in the cortex, striatum, and hippocampus of adult male offspring. We hypothesised 
that late gestation polyI:C offspring would exhibit greater reductions in inhibitory mRNAs versus early gestation 
polyI:C offspring. Additionally, from previous investigations in polyI:C mouse offspring49, we hypothesised that 
polyI:C male offspring (GD10 and GD19 combined) have reduced PVALB mRNA in infralimbic cortex a priori. 
Finally, since inhibitory neurons transverse larger distances to reach the frontal cortex and hippocampus in com-
parison to the striatum, we hypothesised that polyI:C male offspring would exhibit more profound alterations in 
the cortex and hippocampus versus the striatum.
Methods
Animals and prenatal polyI:C administration. Experiments were performed in accordance with the 
National Health and Medical Research Council’s Australian code for the care and use of animals for scientific 
purposes (https://www.nhmrc.gov.au/guidelines-publications/ea28). The current study was approved by the 
University of Newcastle’s Animal Care and Ethics Committee (Approval number A-2009-108). Rats were sourced 
from the University of Newcastle’s Central Animal House and housed in conventional open-top cages with 
ad libitum food (standard rat chow, Specialty Feeds, WA, Australia) and water and 12 h light exposure in the 
University of Newcastle’s Behavioral Sciences Animal Facility.
Nulliparous postnatal day (PND) 70–90 Wistar rats were time-mated and day of vaginal plug detection was 
designated as GD0. Pregnant rats were randomly assigned one of two timing groups: GD10 (n = 8) or GD19 
(n = 7). On the appropriate GD, pregnant rats were weighed, lightly anesthetized with isoflurane, and injected 
intravenously through the tail vein with 0.1 M phosphate-buffered saline (PBS) (control; n = 8) or 4 mg/mL of 
polyI:C (P9582, Sigma-Aldrich; n = 7) in PBS at a volume of 1 mL/kg body weight. To confirm successful MIA, 
saphenous vein blood samples were collected 2 hours after treatment injections. Plasma was used for interleukin-6 
(IL-6) measurement using rat IL-6 Quantikine ELISA (R&D Systems, MN, USA). PolyI:C treated dams had 
significantly increased IL-6 levels (624.7 ± 57.0 pg/mL) compared to saline-injected dams (68.4 ± 57.0 pg/mL) 
(F(1,8) = 50.56, p < 0.001). There was no effect of gestational timing (F(1,8) = 0.24, p > 0.05) or interaction between 
gestational timing and treatment (F(1,8) = 0.23, p > 0.05) on maternal plasma IL-6 levels.
Offspring were weaned on PND 21, separated into same-sex cages in pairs. Male adult offspring from either 
treatment or timing group did not differ in weight at time of euthanasia (GD10 control: 432 ± 32 g, n = 8; GD19 
control: 441 ± 44 g, n = 8; GD10 MIA: 418 ± 47 g, n = 6; GD19 MIA: 415 ± 28 g, n = 6; treatment: F(1,24) = 1.74, 
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Figure 1. Gene expression of inhibitory-related markers quantified in cortex (Ctx), striatum (Str), and 
hippocampus (Hpc) subregions from representative in situ hybridization films when male offspring from 
vehicle (Control) or polyI:C (4 mg/kg) treated dams reached adulthood. (A–D) Grey line schematics of coronal 
sections of rat brain show the cortical (Ctx, A,B), striatal (Str, C,D), and hippocampal (Hpc, B) subregions 
(black outlines from −3.00 to 3.24 mm bregma) that were quantified in this study. (A,B) In rostral (A) and 
caudal (B) cortical sections, three subregions were quantified: infralimbic (solid line), cingulate (dashed 
line), and auditory (dotted line on the right-most side) cortex. (B) In rostral hippocampal sections, three 
subregions were quantified: CA1 (solid line), CA3 (dashed line), and CA4 (dotted line). (C,D) In rostral 
(C) and middle (D) striatal sections, three subregions were quantified: dorsal striatum (solid line), nucleus 
accumbens core (dotted line), and nucleus accumbens shell (dashed line). (E) Representative autoradiographs 
of glutamate decarboxylase-1 (GAD1) mRNA, parvalbumin (PVALB) mRNA, and somatostatin (SST) mRNA 
in situ hybridization films from control and polyI:C offspring. Sections pictured are from postnatal day 70–81 
offspring from the GD10 group. The representative Ctx and Str autoradiographs are from ~2.00 mm bregma 
for GAD1 mRNA, 2.50 mm for PVALB mRNA, and 1.70 mm bregma for SST mRNA. The representative 
Hpc autoradiographs are from ~−3.0 mm bregma. Statistics of treatment effects and treatment × subregion 
interactions are detailed in Table 1 and shown graphically in Fig. 4; there were no treatment × timing 
interactions for any of the markers. Bregma level (mm) is indicated on the left of the schematics. Scale 
bar = 1000 µm.
Transcript Brain region
Treatment Treatment × Timing Treatment × Subregion Treatment × Timing × Subregion
F p F p F p F p
GAD1
Cortex 0.001 0.97 0.912 0.349 0.403 0.61 1.709 0.2
Striatum 0.099 0.755 0.092 0.764 0.601 0.469 0.247 0.66
Hippocampus 0.56 0.461 2.213 0.15 0.846 0.416 0.428 0.614
PVALB
Cortex 2.868 0.106 0.012 0.914 0.241 0.741 0.843 0.418
Striatum 3.286 0.084 0.127 0.725 1.15 0.321 0.29 0.721
Hippocampus 3.716 0.066 0.484 0.494 0.879 0.415 3.176 0.056
SST
Cortex 4.772* 0.043* 0.078 0.783 3.973* 0.035* 0.089 0.89
Striatum 4.926* 0.036* 2.33 0.14 5.532* 0.012* 1.072 0.338
Hippocampus 0.279 0.602 0.324 0.575 0.129 0.825 2.248 0.132
SSTR2
Cortex 0.817 0.376 4.533* 0.045* 0.226 0.752 0.748 0.454
Striatum 1.71 0.203 4.508* 0.044* 2.127 0.133 1.521 0.23
Hippocampus 0.017 0.899 3.067 0.093 0.88 0.399 0.618 0.506
Table 1. Treatment effects and treatment interactions for inhibitory-related transcripts in cortex, striatum, and 
hippocampus. Two-way repeated measure ANOVAs [between-subject variables: treatment (control, polyI:C) 
and timing (GD10, GD19); within-subject variables: three subregions] were conducted per transcript per brain 
region. Significant values (p < 0.05) are bold and accompanied with an asterisk (*). Treatment effects for SST 
mRNA are shown in Figs. 1 and 2. Treatment × timing interactions for SSTR2 mRNA are shown in Figs. 2 and 3. 
Treatment × subregion interactions for SST mRNA are shown in Fig. 1 and Supplementary Fig. 3. *p < 0.05.
4Scientific RepoRtS |         (2020) 10:1982  | https://doi.org/10.1038/s41598-020-58449-x
www.nature.com/scientificreportswww.nature.com/scientificreports/
timing: F(1,24) = 0.032, treatment × timing: F(1,24) = 0.18, all p > 0.05). No more than two male offspring per litter 
were used in each experimental group to avoid litter-effect confounds and were randomly assigned to the study. 
Whole brains, snap-frozen in isopentane (−40 °C) for storage (−80 °C), were sectioned (coronal, 14 μm) using a 
cryostat (Leica, Wetzlar, Germany) and mounted onto gelatin-coated glass slides.
In situ hybridisation. Riboprobes (Supplementary Table 1) were generated with 35S-UTP (CAT# 
NEG039H001MC Perkin Elmer, Waltham, Massachusetts, USA) using an in vitro transcription kit (CAT# P1121, 
Promega, Madison, Wisconsin, USA). In situ hybridisation was performed as previously described57, using 5 ng/
ml radiolabelled riboprobes in hybridisation buffer, and 35S-UTP labelled sense strand riboprobes as a negative 
control (Supplementary Figures 1 and 2). Slides were exposed to BioMax MR (Kodak, Rochester, NY, USA) auto-
radiographic film (Supplementary Table 1) alongside a 14C standard slide (American Radiolabelled Chemicals, 
St. Louis, MO, USA).
Quantification of mRNAs. Developed films were digitised (600dpi, CAT# 8600 F, Canoscan, Canon Inc, 
Japan) and calibrated using NIH imaging software (v1.56; http://rsb.info.nih.gov/nih-image) to produce nCi/mg 
tissue equivalent (t.e.) values based on the standard Rodbard curve obtained from the 14C standards to remove 
background intensity. Optical density values were quantitated using ImageJ (v1.48; https://imagej.nih.gov/ij/) 
and averaged across hemispheres from two to four sections per animal. Cortical [infralimbic (IL), cingulate (Cg), 
auditory (Aud), Fig. 1A,B], striatal [dorsal striatum (DS), nucleus accumbens core (AC), nucleus accumbens shell 
(AS), Fig. 1C,D], and hippocampal [cornu ammonis area 1(CA1), cornu ammonis area 3 (CA3), cornu ammonis 
area 4 (CA4), Fig. 1B] regions were identified as per Paxinos 6th edition Rat Atlas58.
Statistical analysis. Graphs were plotted using Graph Pad Prism (v6) and data analysed with IBM SPSS 
statistics (v23). All data passed Shapiro-Wilk normality tests. Three-way mixed analysis of variance (ANOVA) 
was conducted for each region (cortex, striatum, and hippocampus), separately; hence there were three 2 × 2 × 3 
repeated-measure (RM) ANOVAs in total. For each of these analyses, the two between-subject factors were treat-
ment (polyI:C or vehicle) and timing (GD10 or GD19), and the within-subject factor was subregions (cortical 
subregions: IL, Cg, and Aud cortex; striatal subregions: DS, AC, and AS; hippocampal subregions: CA1, CA3, 
and CA4). Bonferroni tests were used for pairwise comparisons when the overall ANOVA was significant. The 
Greenhouse Geisser correction was used if Mauchley’s sphericity test was violated for within-subjects interac-
tion effects. Deming regressions were conducted to query the relationship between each offsprings’ regional 
gene expression of each marker and their respective maternal IL-6 protein exposure. Data are expressed as the 
mean ± standard error of the mean (SEM) and two-sided p < 0.05 was deemed statistically significant.
Results
GAD1 mRNA signals were punctate in the cerebral cortex and hippocampus, and darker and more homogeneous 
across the striatum (Fig. 1E). PVALB mRNA signals were punctate in the cerebral cortex, hippocampus, and stri-
atum. PVALB mRNA signals in the cortex was stronger and denser in comparison to signals in the hippocampus 
and striatum (Fig. 1E). SST mRNA signals were punctate in all regions, and denser in the cerebral cortex in com-
parison to the hippocampus and striatum (Fig. 1E). SSTR2 mRNA signals were highest in the molecular layer of 
the hippocampus, followed by the deeper layers of the cerebral cortex, the superficial layers of the cerebral cortex, 
and then the striatum (Fig. 2).
GAD1 mRNA59,60, PVALB mRNA61, and SST mRNA62 signals correspond to previously described distribu-
tions. Although cortical SSTR2 mRNA signals were lighter in comparison to some studies63, the distribution cor-
responds to SSTR2 mRNA and SSTR2 binding results in multiple other studies (Supplementary Figure 1A)64–68. 
Control (sense) riboprobe hybridization, for all transcripts, was at background levels (Supplementary Figure 1B, 
2).
There was a main effect of subregion on the expression pattern of GAD1 mRNA, PVALB mRNA, SST mRNA, 
and SSTR2 mRNA for cortical, striatal, and hippocampal comparisons in all offspring, except for SST mRNA in 
hippocampus (Supplementary Table 2). A summary of all treatment effects and treatment-related interactions 
are highlighted in Table 1. Briefly, there were significant treatment effects for SST mRNA in cortex (Fig. 3A) and 
striatum (Fig. 3B), treatment × timing interactions for SSTR2 mRNA in cortex (Fig. 3A) and striatum (Fig. 3B), 
and treatment × subregion interactions for SST mRNA in cortex (Fig. 4A) and striatum (Fig. 4B). There were no 
significant treatment × timing × subregion interactions for any of the markers (Supplementary Figure 3A–C).
Cortical PVALB mRNA and SST mRNA are reduced in polyI:C offspring in a subregion-specific 
manner, whereas cortical SSTR2 mRNA is reduced in polyI:C offspring in a timing-specific manner. 
GAD1 mRNA was not changed by MIA exposure in cortex (F(1, 24) < 0.01, p = 0.97; Fig. 3A). Additionally, there were 
no treatment × timing (F(1, 24) = 0.91, p = 0.35; Fig. 3A), treatment × subregion (Fig. 4A) or treatment × timing 
× subregion (F(1.5,35.5) < 1.0, p > 0.05; Supplementary Figure 3A) interaction effects on GAD1 mRNA (Table 1).
There was no overall effect of MIA treatment (F(1, 20) = 2.87, p = 0.11; Fig. 3A) on PVALB mRNA in cortex. 
Additionally, there were no treatment × timing (F(1, 20) = 0.01, p = 0.91; Fig. 3A), treatment × subregion (Fig. 4A) 
or treatment × timing × subregion (F(1,40) < 1.0, p > 0.05; Supplementary Figure 3A) interaction effects on PVALB 
mRNA (Table 1). As expected, PVALB mRNA was reduced by 22% in the IL cortex of polyI:C offspring (a priori 
univariate ANOVA: F(1, 22) = 5.08, p = 0.04; Fig. 4A).
There was a significant effect of MIA treatment on SST mRNA cortex, where polyI:C offspring had 20% less 
SST mRNA versus controls (F(1,17) = 4.77, p = 0.04; Fig. 3A). There were no treatment × timing (F(1, 17) = 0.08, 
p = 0.78; Fig. 3A) or treatment × timing × subregion (F(2,34) = 0.09, p = 0.92; Supplementary Figure 3A) interac-
tion effects on SST mRNA (Table 1). There was a treatment × subregion interaction effect (F(2,34) = 3.97, p = 0.03, 
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Fig. 4A) where polyI:C offspring had 33% less SST mRNA in Cg cortex (F(1,17) = 9.03, p < 0.01), but not in IL cor-
tex (F(1,17) = 0.19, p = 0.67) or in Aud cortex (F(1,17) = 2.78, p = 0.11), compared to control offspring.
There was no overall effect of MIA on SSTR2 mRNA in cortex (F(1, 22) = 0.82, p = 0.38; Fig. 3A). However, there 
was a significant treatment × timing interaction effect (F(1, 22) = 4.53, p = 0.04) where MIA offspring had 14% less 
SSTR2 mRNA in cortex at GD19 (F(1,22) = 4.49, p < 0.05; Fig. 3A grey dotted bars), but not GD10 (F(1,22) = 0.77, 
p = 0.39; Fig. 3A white dotted bars), compared to controls (Fig. 3A white and grey solid bars). There were no treat-
ment × subregion (Fig. 4A) or treatment × timing × subregion (Supplementary Figure 3A) interaction effects on 
SSTR2 mRNA (F(2,44) < 1.0, p > 0.05, Table 1).
Striatal SST mRNA is reduced in polyI:C offspring in a subregion-specific manner, whereas stri-
atal SSTR2 mRNA is reduced in polyI:C offspring in a timing-specific manner. GAD1 mRNA (F(1, 24) 
= 0.10, p = 0.76) and PVALB mRNA (F(1, 22) = 3.29, p = 0.08) were not affected in the striatum by MIA (Fig. 3B). 
There were no treatment × timing effects for GAD1 mRNA (F(1, 24) = 0.09, p = 0.76) or PVALB mRNA (F(1, 22) 
= 0.13, p = 0.73) in striatum (Fig. 3B). There were also no treatment × subregion (Fig. 4B) or treatment × tim-
ing × subregion interaction effects (Supplementary Figure 3B) for GAD1 mRNA (F(1.2,28.0) < 1.0, p > 0.05) or 
PVALB mRNA (F(2,44) < 1.15, p > 0.05; Table 1).
There was a significant effect of MIA treatment on SST mRNA striatum, where polyI:C offspring had 17% 
less SST mRNA versus controls (F(1,24) = 4.93, p = 0.04; Fig. 3B). There were no treatment × timing (F(1, 24) = 2.33, 
p = 0.14; Fig. 3B) or treatment × timing × subregion (F(1.6,37.6) = 1.07, p = 0.35; Supplementary Figure 3B) 
Figure 2. Representative autoradiographs of somatostatin receptor 2 (SSTR2) mRNA in situ hybridisation. 
Pregnant dams were treated with vehicle (Control, top) or 4 mg/kg polyriboinosinic:polyribocytidilic acid 
(PolyI:C, bottom) during early gestation (GD10, left) or late gestation (GD19, right). Coronal sections from 
~2.3 mm bregma for cortex (Ctx) and striatum (Str), and ~−3.0 mm bregma for hippocampus (Hpc) were 
processed when offspring reached adulthood. GD19 polyI:C offspring had significant reductions of SSTR2 
mRNA in cortex and striatum compared to controls. Sections pictured are from postnatal day 77–84 offspring. 
Statistics of treatment × timing interactions for SSTR2 mRNA are shown in Table 1 and shown graphically in 
Fig. 3. Scale bar = 1000 µm. The values to the right of the figures denote the average signal intensity ± S.E.M. 
(nCi/g) of the three cortical [infralimbic (not visible on image), cingulate, auditory (not visible on image)], 
striatal (dorsal striatum, nucleus accumbens shell, nucleus accumbens core), and hippocampal (CA1, CA3, DG) 
subregions quantified from the animals portrayed in the representative autoradiographs.
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interaction effect on SST mRNA. There was a treatment × subregion interaction effect (F(1.6,37.6) = 5.53, p < 0.01) 
where polyI:C offspring had 29% less SST mRNA in the nucleus accumbens shell (AS) (F(1,24) = 7.37, p = 0.01; 
Fig. 4B), but not dorsal striatum (DS) (F(1,24) = 0.366, p = 0.51; Fig. 4B), compared to control offspring. The pair-
wise comparison of SST mRNA in the nucleus accumbens core (AC) did not reach significance (F(1,24) = 3.89, 
p = 0.06; Fig. 4B).
There was no overall effect of MIA on SSTR2 mRNA in striatum (F(1, 24) = 1.71, p = 0.20; Fig. 3B). However, 
there was a significant treatment × timing interaction effect (F(1,24) = 4.51, p = 0.04) where MIA offspring had 33% 
less SSTR2 mRNA in striatum at GD19 (F(1, 24) = 5.89, p = 0.02; Fig. 3B), but not GD10 (F(1,24) = 0.33, p = 0.57; 
Fig. 3B), compared to controls. There were no treatment × subregion (Fig. 4B) or treatment × timing × subregion 
(Supplementary Figure 3B) interaction effects on SSTR2 mRNA (F(2,48) < 2.13, p > 0.05, Table 1).
Hippocampal gene expression of GAD1, PVALB, SST, or SSTR2 is not altered in polyI:C off-
spring in a subregion- or timing-specific manner. MIA exposure did not significantly alter GAD1 
mRNA (F(1, 24) = 0.56, p = 0.46), PVALB mRNA (F(1, 23) = 3.72, p = 0.07), SST mRNA (F(1,23) = 0.28, p = 0.60), 
or SSTR2 mRNA (F(1,24) = 0.24, p = 0.63) in hippocampus (Fig. 3C). Further, there were no treatment × timing 
Figure 3. Somatostatin receptor 2 (SSTR2) mRNA is decreased in offspring exposed to polyI:C on GD19, not 
GD10, in cortex and striatum. Pregnant dams were treated with vehicle (control, solid bar) or 4 mg/kg polyI:C, 
(dotted bar) during early gestation (GD10, white) or late gestation (GD19, grey). Glutamate decarboxylase-
1(GAD1), parvalbumin (PVALB), somatostatin (SST), and somatostatin receptor 2 (SSTR2) mRNAs were 
quantified in (A) cortex, (B) striatum, and (C) hippocampus from adult offspring. Data shown are pooled 
over three subregions for each region (cortex, striatum, and hippocampus. There was no overall treatment or 
treatment × timing interaction effect for GAD1 or PVALB mRNAs in any region. There was an overall treatment 
effect for SST mRNA in (A) cortex and (B) striatum, but not (C) hippocampus, (refer also to Table 1). There was 
a treatment × timing interaction for SSTR2 mRNA in (A) cortex and (B) striatum, but not (C) hippocampus, 
(refer also to Table 1). At GD10, there was no change in SSTR2 mRNA levels observed between control and 
polyI:C offspring. At GD19, polyI:C offspring showed reduced SSTR2 mRNA in (A) cortex by 29%, and in (B) 
striatum by 17% versus control offspring. Data are mean ± SEM (n = 6–8 rats per treatment and timing group). 
*p < 0.05.
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interaction effects for GAD1 mRNA (F(1, 24) = 2.21, p = 0.15), PVALB mRNA (F(1, 23) = 0.48, p = 0.49), SST mRNA 
(F(1, 23) = 0.32, p = 0.58), or SSTR2 mRNA (F(1, 24) = 2.62, p = 0.12) in hippocampus (Fig. 3C). Finally, there were 
no treatment × subregion (Fig. 4C) or treatment × timing × subregion (Supplementary Figure 3C) interaction 
effects on GAD1 mRNA (all F(1.6,39.1) < 0.85, p > 0.05), PVALB mRNA (all F(2,46) < 3.18, p > 0.05), SST mRNA (all 
F(1.5,35.2) < 2.25, p > 0.05), or SSTR2 mRNA (all F(2,48) < 1.72, p > 0.05) in hippocampus (Table 1).
Maternal IL-6 response to polyI:C treatment is related to SST mRNA in the cortex and striatum, 
but not hippocampus of offspring. Across all offspring (treatment and timings combined), there was a 
significant negative relationship between maternal IL-6 protein two hours after treatment and adult offspring SST 
mRNA in cortex (F(1,18) = 4.39, p = 0.05) and striatum (F(1,21) = 9.59, p < 0.01), but not hippocampus (F(1,20) = 0.44, 
p = 0.52). The slopes were of moderate strength (cortex: R2 = 0.196, striatum: R2 = 0.314; Supplementary 
Figure 4). No significant relationships were found between maternal IL-6 protein two hours after treatment and 
adult offspring GAD1 mRNA (cortex: F(1,21) = 0.16, all p = 0.70; striatum: F(1,21) = 0.19, all p = 0.67; hippocam-
pus: F(1,21) = 0.35, p = 0.56), PVALB mRNA (cortex: F(1,17) = 0.64, p = 0.43; striatum: F(1,19) = 2.58, all p = 0.12; 
hippocampus: F(1,20) = 0.39, p = 0.54), or SSTR2 mRNA (cortex: F(1,21) = 0.46, p = 0.50; striatum: F(1,21) = 1.74, all 
p = 0.20; hippocampus: F(1,21) = 4.04, p = 0.06) levels in any brain region (Supplementary Figure 4).
Discussion
Our findings demonstrate differential, long-term impacts of early gestation and late gestation MIA on inhibitory 
indices within the cortex and striatum of adult rat polyI:C offspring. As hypothesised, we found PVALB mRNA 
reductions in the infralimbic cortex of polyI:C offspring, which aligns with previous studies that report reduc-
tions in PVALB-positive cells in the medial prefrontal cortex in both early gestation and late gestation adult49,52 
Figure 4. Inhibitory neuron gene expression is altered in subregions of (A) cortex and (B) striatum, but not 
(C) hippocampus, in adult male polyI:C offspring. Pregnant dams were treated with vehicle (Control, grey) or 
4 mg/kg (PolyI:C, dotted) during either early gestation or late gestation (data herein represent gestational timing 
combined, data is presented separately in Supplementary Fig. 3). Glutamate decarboxylase 1 (GAD1) parvalbumin 
(PVALB), somatostatin (SST) and somatostatin receptor 2 (SSTR2) mRNAs were quantified in vehicle (control, 
grey bar) and polyI:C (dotted bar) offspring. Treatment × subregion interaction effects were not present for GAD1 
or SSTR2 mRNAs in any subregion. PolyI:C offspring had reductions in PVALB mRNA in the infralimbic cortex 
compared to controls (a priori univariate ANOVA: F(1, 22) = 5.08, p = 0.04). SST mRNA was significantly reduced 
in (A) cingulate cortex and (B) nucleus accumbens shell of the striatum in polyI:C offspring. Refer to Table 1 for 
treatment × subregion interaction for SST mRNA. Data are mean ± SEM (n = 12–16 rats per group). Infralimbic 
cortex (IL), cingulate cortex (CG), auditory cortex (AUD), dorsal striatum (DS), nucleus accumbens core (AC), 
nucleus accumbens shell (AS), cornu ammonis (CA). #p < 0.05, **p < 0.01.
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and juvenile53 mouse polyI:C offspring. Somewhat surprisingly, we did not find significant changes in the inhib-
itory neuron marker, GAD1 mRNA, in cortical subregions, and no significant changes in either PVALB or GAD1 
mRNAs in the hippocampus of polyI:C offspring. Although this lack of apparent change in GAD1 mRNA aligns 
with the majority of the reports in polyI:C offspring, methodological variations may contribute to inconsistent 
findings in the field (see Supplementary Table 3 for a brief overview). We also report no significant changes in 
either PVALB or GAD1 mRNA in the striatum. Although, to our knowledge, there have been no investigations of 
PVALB gene expression in the striatum of adult polyI:C offspring, our results align with studies that also find no 
significant change in GAD1 mRNA in the striatum of GD14 polyI:C adult rat offspring38. Our findings suggest 
that some inhibitory neuron deficits may not consistently result from MIA, or may arise due to MIA at a different 
gestational time point. Further, we acknowledge that our sample size may not detect subtle changes. Indeed, we 
find approximate trend reductions in PVALB mRNA in the cortex (p < 0.11), striatum (p < 0.09) and hippocam-
pus (p < 0.07) of MIA offspring, and qualitative observation of our data suggests that this may arise from MIA at 
GD19. Our data suggests that future studies are warranted with larger sample sizes to investigate the effect of MIA 
timing on these inhibitory markers, particularly GAD1 and PVALB.
We present the first report of reduced SST mRNA in both cortex and striatum in the rat MIA model of schizo-
phrenia. In the cortex of people with schizophrenia, SST mRNA reductions are typically of a larger magnitude and 
can be as robust (if not more robust) than the more often studied PVALB mRNA changes8,20,21,24, with widespread 
decreases in SST mRNA reported in dlPFC, orbital frontal cortex, anterior cingulate cortex, motor cortex, and 
visual cortex8,20,21,24. The anatomically specific MIA-induced reductions in SST mRNA in the cingulate cortex, 
but not in infralimbic and auditory cortex, suggest that MIA may impact specific circuitry differentially. If MIA 
alone is not sufficient to recapitulate the fairly pervasive cortical reductions in SST mRNA observed in people 
with schizophrenia8,20,21,24,69, a subsequent postnatal stressor, or ‘second hit’, may be needed to elicit a widespread 
change in SST gene expression in the MIA model [see70 for review]. The SST mRNA deficits detected in the cortex 
and striatum, but not hippocampus, may relate to the distinct origins of inhibitory neurons in these regions. In 
cortex, the majority of PVALB- and SST-containing inhibitory neurons are derived from the medial ganglionic 
eminence (MGE) (71, see72 for review). In hippocampus, although some PVALB- and SST-containing inhibi-
tory neurons also arise from the MGE, approximately 40% of SST-containing inhibitory neurons are derived 
from the caudal ganglionic eminence (CGE)73. The dominant period of MGE neurogenesis (GD9.5-GD13.5) 
precedes that of CGE neurogenesis (GD12.5–16.5)74,75. It is possible that the time points we chose to elicit MIA 
may alter neurogenesis for each ganglionic eminence distinctly and somewhat spare the interneurons destined 
for the hippocampus.
We also present the first report of cortical and striatal SSTR2 mRNA reductions in a rodent MIA model of 
schizophrenia, which aligns with the SSTR2 mRNA reduction seen in the cortex of people with schizophrenia26. 
Reductions in both regions, however, are contrary to our hypothesis that postulated that the cortex is more sus-
ceptible to MIA than the striatum. Given that our previous behavioural study showed working memory impair-
ments in GD19 polyI:C offspring, but not GD10 polyI:C offspring50, and multiple studies show a central role of 
somatostatinergic signalling in cognitive function76–79, our present findings suggest that the combined SSTR2 
mRNA deficits in cortex and striatum (found only at GD19), in combination with the SST mRNA deficits in 
cortex and striatum, may contribute to the working memory deficits apparent in late gestation MIA offspring. 
Qualitative observation of our data shows that SST mRNA deficits in cortex in polyI:C offspring seem to occur at 
both GD10 and GD19, whereas SST mRNA deficits in striatum in polyI:C offspring seem driven by MIA at GD10. 
This is possibly evidence of a timing-specific effect of MIA in striatum but not cortex; however, we did not detect 
a significant treatment × timing interaction effect or treatment × timing × subregion interaction effect that would 
permit us to investigate these further. Our data suggests that future studies are warranted with larger sample sizes 
may reveal significant effects of MIA timing on inhibitory markers in offspring.
Further, maternal IL-6 elevations are prolonged when polyI:C is administered in rodent dams during late 
gestation versus early gestation80, and maternal IL-6 levels in humans are associated with altered offspring neo-
natal functional connectivity and cognitive outcome81–84. Although we only measured maternal IL-6 at one time 
point, we also report a moderate negative relationship between maternal IL-6 and offspring SST gene expression 
in cortex and striatum. Overall, our data supports the notion that SST and SSTR2 gene expression deficits may 
contribute to the working memory deficits apparent in late gestation MIA offspring.
Increased SST-positive interstitial white matter neurons (IWMN) and concurrent decreases in SST mRNA 
in the grey matter is reported in post-mortem frontal cortex from schizophrenia cases24,85. Recent studies show 
that both early gestation and late gestation polyI:C treatment increased the number of SST-positive IWMNs in 
regions that extend underneath the cingulate cortex in adult rat offspring86. Our detection of reduced SST mRNA 
in the grey matter suggests MIA during either the initial development of the ganglionic eminence54, or the time of 
neuronal tangential migration55,56 could alter the migration or survival of SST cortical interneurons. Interestingly, 
late gestation polyI:C offspring exhibit increased SST-positive IWMNs in more extensive regions of white matter 
compared to early gestation polyI:C offspring86. Given that SSTR2 is highly expressed on migrating neurons 
during early neurodevelopment in both rat and human87, our present findings may indicate a link between exag-
gerated IWMN pathology and SSTR2 deficits in late gestation polyI:C offspring. Indeed, reductions in SST mRNA 
and reductions in SSTR2 mRNA are correlated in dlPFC in schizophrenia26.
Overall, our current and prior findings are consistent with our hypothesis and earlier findings that gestational 
inflammation contributes to inhibitory neurotransmission deficits. This supports the growing evidence of altered 
inhibitory indices in the cortex and striatum of adult polyI:C offspring and recapitulates some aspects of neu-
ropathology present in schizophrenia. We present the first rodent MIA study of cortical and striatal deficits in 
SST and SSTR2 gene expression that concurs with cortical SST and SSTR2 mRNA deficits found in post-mortem 
schizophrenia studies. Our novel finding of SST and SSTR2 mRNA reductions in striatum suggests that further 
examination of SST-related neurotransmission may be warranted in the striatum of people with schizophrenia. 
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Although our data provide clues as to how inflammation, at different times during gestation, may contribute to 
schizophrenia-like pathologies, multiple gestational inflammatory insults and/or postnatal “second-hit” stress-
ors are likely required to produce the large spectrum of symptoms and cognitive deficits that culminate in the 
diagnosis of schizophrenia. We postulate that somatostatinergic alterations could contribute to cognitive deficits 
previously reported in adult polyI:C offspring and in people with schizophrenia. Links between specific risk fac-
tors, such as maternal inflammation, and molecular alterations are critical to the development of mental illnesses, 
and we have identified SST and its receptor, SSTR2, as potential mediators of gestational inflammation-related 
risk for schizophrenia.
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